

# A Plain-Language Tool to Bridge the Health Literacy Gap for People with Inherited Cancer Risk

Diane Rose<sup>1</sup>, Susan J. Friedman<sup>1</sup>, Juanita Rogers<sup>1</sup>, Kelly N. Owens<sup>1</sup>, Piri L. Welcsh<sup>1</sup>, Marleah Dean<sup>2</sup>, Robin H. Pugh Yi<sup>3</sup>

1. Facing Our Risk of Cancer Empowered, Tampa, FL., USA, 2. Dept. of Communication, University of South Florida, Tampa, FL, USA , 3. Akeso Consulting, Vienna, VA, USA

## INTRODUCTION

Background: Although numbers are improving, patient participation in clinical cancer research remains low.

Issue: Gaps in patient and provider awareness of clinical research opportunities, jargon, and hard-to-navigate study listings contribute to low participation.

FORCE's Approach: FORCE's "Search and Enroll Tool" is a custom-designed database that curates and disseminates plain-language summaries of clinical research studies enrolling people with inherited mutations.

Conclusion: Users find the tool easy to use, and they are able to understand study eligibility and what is required of participants. Many users subsequently enrolled or intend to enroll in a hereditary cancer research study.

## BACKGROUND


Only 7% of adult cancer patients enroll in treatment-related clinical trials, with even lower rates for genetics and quality-of-life studies.<sup>1</sup> Low enrollment in clinical trials leads to early study closures, slower progress and increased costs, with the possibility of poorer outcomes for cancer patients.

People with inherited mutations are interested in participating in hereditary cancer research, but few are being offered the opportunity by their healthcare team. In a

2024 FORCE survey, only 14% of people with inherited risk for breast cancer reported hearing about clinical research

options from their healthcare providers, while 74% expressed interest.<sup>2</sup> Similar trends were reported by people at high risk for gynecologic and colorectal cancer.<sup>3</sup>

The development of cancer targeted therapies and new approaches to prevention and interception have led to an increase in research studies enrolling people with germline mutations. Dedicated efforts are needed to ensure that the hereditary cancer community is aware of clinical research opportunities.




## HEALTH LITERACY IS A BARRIER

In 2020 FORCE surveys, 46% of oncology nurse and 55% of genetic counselors identified research jargon and health literacy as a major barrier to clinical trial referrals.<sup>4,5</sup>

In 2020, FORCE and other advocacy group members of the Consistent Testing Terminology Working Group surveyed patients with or at high risk for cancer about familiarity with terminology frequently used in research and found significant gaps in patient understanding of terms commonly used to in cancer research.<sup>6</sup>

How familiar are you with the following terms related to cancer?



In 2024, FORCE conducted focus groups of 24 women with or at high risk for hereditary breast cancer. Participants reviewed a cancer treatment and prevention study listing on ClinicalTrials.gov. All agreed that the study description was difficult to understand due to complexity and academic jargon and all agreed that ClinicalTrials.gov required a lot of time and practice to find studies relevant to their situation.<sup>7</sup>

## FORCE SEARCH AND ENROLL TOOL

In 2014, FORCE built our "Search and Enroll Tool" to help hereditary cancer patients find, understand, and enroll in relevant studies. The tool consists of a custom database with plain-language summaries of clinical research studies relevant for people with inherited cancer risk. Features include:

- Plain language descriptions of study goals, eligibility, and what will be required of participants.
- Built-in glossary.
- Printer-friendly version of study listings.
- Users can search for featured studies in the FORCE database and on ClinicalTrials.gov. Users can search by study type, cancer type, gene or biomarker, study location or key word.

**Printer-friendly option**

**Plain language overview**

**Built-in glossary**

**Study contact**

**Plain language inclusion & exclusion criteria**

**This Study is Open To:**

Women can participate if:

- they are aged 35 to 50.
- have an inherited mutation in BRCA1.
- are planning to have surgery to reduce the risk of ovarian cancer.
- are premenopausal or menopausal.
- have at least one ovary and fallopian tube.

**This Study is Not Open To:**

People are excluded if they:

- have had prior cancer and received chemotherapy within the past 30 days.
- People who are receiving maintenance HER2 therapy (trastuzumab, pertuzumab) or hormonal therapy may still participate.
- have received radiation therapy to abdomen or pelvis at any time.
- have a history of ovarian, primary peritoneal, or fallopian tube cancer.
- cannot tolerate surgery or general anesthesia.
- desire to become pregnant naturally in the future. People who plan to become pregnant through assisted reproductive technologies such as in-vitro fertilization (IVF) may still participate.

**A STUDY TO COMPARE TWO SURGICAL PROCEDURES IN WOMEN WITH BRCA1 MUTATIONS TO ASSESS REDUCED RISK OF OVARIAN CANCER (SOROCK)**

**About the study**

SOROCK [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes in women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes is to prevent surgically-induced menopause. The study will also examine various patient health and life outcomes. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer. This concept has never been formally testing in a clinical trial.

For more information, visit <https://clinicaltrials.gov/show/NCT04251052>.

## Study listing features


## PROGRAM USER FEEDBACK

To evaluate FORCE's Search and Enroll Tool, FORCE has collected program feedback via an online survey since 2019.


Of 808 respondents, 81% indicated they were looking for screening or prevention studies, 58% were looking for studies on genetic counseling, testing or cancer risk, 49% were looking for studies on long-term health outcomes, 40% were looking for treatment studies, and 40% were looking for studies on behavioral health or quality of life.

Key results include:

- 85% were able to understand the study goals.
- 85% were able to understand what was required of participants.
- 85% were able to understand who was eligible for the study.



Of the respondents, almost 38% stated that they had enrolled in a research study and 43% responded that they planned to enroll in a study.



*I've found studies for myself, my sister and my daughter. It's empowering to help researchers understand hereditary cancers.*

– Program user

*I appreciate having this information readily available. It's easier to find relevant studies than having to sort through the NIH website.*

– Program user

## CONCLUSIONS

People with inherited cancer risk are highly motivated to participate in clinical research—but most are never informed about available studies by their healthcare team.

ClinicalTrials.gov is not patient-friendly and hereditary cancer patients find the site difficult to use and understand.

FORCE's Search and Enroll Tool bridges this gap by offering accessible, accurate, and easy-to-understand listings of studies enrolling hereditary cancer patients.

Results from our focus groups and survey demonstrate that the tool meets a critical need. Users reported high satisfaction, comprehension, and utilization of the tool to enroll in studies.

## REFERENCES

1. Joseph M. Unger et al. National Estimates of the Participation of Patients With Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation Data. JCO 42, 2139-2148(2024).
2. "Results from FORCE's 2024 Survey Highlighting the Needs of People at High Risk for Breast Cancer." FORCE blog, October 2024.
3. Unpublished.
4. Clark E, Bonini K, et. al. Experiences of Genetic Counselors in Referring Young and Metastatic Breast Cancer Patients to Support Services: A Needs Assessment. Patient Education and Counseling Volume 116, November 2023.
5. Owens K, Dean M, et. al. Needs of Oncology Nurse Navigators Serving Young or Metastatic Breast Cancer Patients. J. of Onc. Navigation & Survivorship, Vol. 15, Num.4, April, 2024.
6. Martin N, Friedman S, et. al. Using consistent terms in precision medicine to eliminate patient confusion... JCO 38, e24164-e24164(2020).
7. Unpublished.